Shares of Genomic Health, Inc. (NASDAQ:GHDX) have earned an average rating of “Hold” from the eleven brokerages that are currently covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $69.60.
A number of research analysts have commented on the company. ValuEngine downgraded Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday, September 10th. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th.
Shares of GHDX stock remained flat at $$63.44 during trading hours on Friday. The firm has a market cap of $2.38 billion, a PE ratio of 60.42 and a beta of 0.90. Genomic Health has a 12-month low of $50.77 and a 12-month high of $90.18. The firm has a 50-day moving average of $65.77 and a 200 day moving average of $64.53. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.96 and a current ratio of 5.96.
Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Monday, November 11th. The medical research company reported $0.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.11. Genomic Health had a return on equity of 19.62% and a net margin of 12.81%. Equities analysts anticipate that Genomic Health will post 1.58 earnings per share for the current fiscal year.
In related news, CEO Kimberly J. Popovits sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $72.53, for a total transaction of $725,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Laura Leber sold 13,183 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $70.94, for a total value of $935,202.02. The disclosure for this sale can be found here. Insiders sold a total of 114,743 shares of company stock valued at $8,125,643 over the last ninety days. Company insiders own 31.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. boosted its holdings in shares of Genomic Health by 316.4% during the second quarter. Invesco Ltd. now owns 687,787 shares of the medical research company’s stock valued at $40,009,000 after acquiring an additional 522,627 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Genomic Health by 18.3% in the 2nd quarter. Renaissance Technologies LLC now owns 2,814,500 shares of the medical research company’s stock worth $163,719,000 after acquiring an additional 435,000 shares during the period. Nuveen Asset Management LLC acquired a new stake in shares of Genomic Health in the 2nd quarter worth about $25,290,000. Vanguard Group Inc. increased its holdings in shares of Genomic Health by 12.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,828,265 shares of the medical research company’s stock worth $164,520,000 after acquiring an additional 305,047 shares during the period. Finally, Carillon Tower Advisers Inc. lifted its position in Genomic Health by 445.4% in the 3rd quarter. Carillon Tower Advisers Inc. now owns 356,393 shares of the medical research company’s stock valued at $24,171,000 after purchasing an additional 291,047 shares during the last quarter. 93.87% of the stock is currently owned by hedge funds and other institutional investors.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
See Also: Bollinger Bands
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.